(Q41519191)

2 October 2017

1 reference

title

An overview of metformin in the treatment of type 2 diabetes mellitus (English)

1 reference

2 October 2017

1 reference

1 reference

2

1 reference

2 October 2017

Davidson MB

1

1 reference

2 October 2017

language of work or name

English

0 references

publication date

1 January 1997

1 reference

American Journal of Medicine

2 October 2017

published in

1 reference

2 October 2017

volume

102

1 reference

2 October 2017

issue

1

1 reference

2 October 2017

page(s)

99-110

1 reference

Management of non-insulin-dependent diabetes mellitus

2 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Pathogenesis of non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Diabetes in identical twins. A study of 200 pairs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Treatment of NIDDM with insulin agonists or substitutes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Management of Non-Insulin-Dependent Diabetes Mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Mechanism of metformin action in non-insulin-dependent diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Cellular mechanism of action of metformin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Metformin increases insulin sensitivity and basal glucose clearance in Type 2 (non-insulin dependent) diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in L6 muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Stimulation of hexose transport by metformin in L6 muscle cells in culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Metformin blocks downregulation of cell surface GLUT4 caused by chronic insulin treatment of rat adipocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Association of Metformin's Effect to Increase Insulin-Stimulated Glucose Transport With Potentiation of Insulin-Induced Translocation of Glucose Transporters From Intracellular Pool to Plasma Membrane in Rat Adipocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

In vivo metformin treatment ameliorates insulin resistance: evidence for potentiation of insulin-induced translocation and increased functional activity of glucose transporters in obese (fa/fa) Zucker rat adipocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Glucose transport in human skeletal muscle cells in culture. Stimulation by insulin and metformin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Metformin increases glucose transporter protein and gene expression in human fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Effect of metformin on insulin-stimulated glucose turnover and insulin binding to receptors in type II diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Metabolic effects of metformin in non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Low dose metformin in the treatment of type II non-insulin-dependent diabetes: clinical and metabolic evaluations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Metformin and metoprolol CR treatment in non-obese men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

The effects of metformin on adipocyte insulin action and metabolic control in obese subjects with type 2 diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Metformin normalizes insulin binding to monocytes from obese nondiabetic subjects and obese type II diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Insulin Receptor Binding to Monocytes, Insulin Secretion, and Glucose Tolerance Following Metformin Treatment: Results of a Double-Blind Cross-Over Study in Type II Diabetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Metformin kinetics in healthy subjects and in patients with diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Role of metformin in treatment of diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Acarbose for the treatment of type II diabetes: the results of a Canadian multi-centre trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Reduction of metformin renal tubular secretion by cimetidine in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Pharmacokinetics of metformin after intravenous and oral administration to man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Double-blind evaluation of efficacy and tolerability of metformin in NIDDM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

The effect of metformin on glycaemic control, intermediary metabolism and blood pressure in non-insulin-dependent diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Comparison of chlorpropamide and metformin treatment on weight and blood-glucose response of uncontrolled obese diabetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Comparison of metformin and chlorpropamide in non-obese, maturity-onset diabetics uncontrolled by diet

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

The reduction of low density lipoprotein cholesterol by metformin is maintained with long-term therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Metformin-induced changes in serum lipids, lipoproteins, and apoproteins in non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Metformin and blood pressure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Comparison of combined therapies in treatment of secondary failure to glyburide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Insulin secretion and action in noninsulin-dependent diabetes mellitus. Is insulin resistance secondary to hypoinsulinemia?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Epidemiology of adverse drug reactions to phenformin and metformin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Malabsorption of Vitamin B12 in Diabetic Patients Treated with Phenformin: A Comparison with Metformin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

Comparative tolerability profiles of oral antidiabetic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900353-1

10.1016/S0002-9343(96)00353-1

7 January 2021

Identifiers

DOI

1 reference

2 October 2017

1 reference